Slide 1: Third Quarter Fiscal 2026 Results
Third Quarter Fiscal 2026 Results February 5, 2026 © 2026 Haemonetics Corporation
Slide 2: Q3 Fiscal 2026 Conference Call Detail
Q3 Fiscal 2026 Conference Call Detail Conference call will take place at 8:00 a.m. ET on Conference call speakers: February 5, 2026, and can be accessed via live webcast: Link or teleconference: Link. Chris Simon The earnings release, accompanying slides and a President & CEO replay of the conferenc
Slide 3: Important Information
Important Information Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historic
Slide 4: Q3 Fiscal 2026 Highlights
Q3 Fiscal 2026 Highlights Delivering earnings growth and margin expansion despite last year’s portfolio transitions • (3%) reported revenue decline; 1% organic1 revenue growth; 8% organic ex-CSL2 revenue growth. • Gross margin up 420bps Y/Y to 59.7%; Adjusted gross margin up 250bps Y/Y to 60.2%. • O
Slide 5: Q3 Fiscal 2026 Revenue by Business Unit
Q3 Fiscal 2026 Revenue by Business Unit Revenue (in millions) Organic Reported Organic Q3 2026 Q3 2025 growth, $349 growth growth $339 (in millions) ex-CSL Plasma $138.9 $134.2 3.5% 2.8% 20.2% Apheresis $56.6 $55.4 2.1% 2.8% 2.8% Whole Blood – $15.0 (100.0%) – – Blood Center $56.6 $70.3 (19.6%) 2.8%
Slide 6: Q3 Fiscal 2026 Financial Review
Q3 Fiscal 2026 Financial Review GAAP Results: Non-GAAP Results: Q3 2026 Q3 2025 Y/Y Q3 2026 Q3 2025 Y/Y Gross Margin % 59.7% 55.5% +420bps Adjusted Gross Margin % 60.2% 57.7% +250bps Operating Margin % 19.9% 16.9% +300bps Adjusted Operating Margin % 26.3% 25.7% +60bps Net Income Margin % 13.2% 10.8%
Slide 7: Q3 Fiscal 2026 Segment Performance
Q3 Fiscal 2026 Segment Performance Plasma Q3 2026 Q3 2025 Y/Y Revenue $138.9M Performance$134.2M Highlights: 3.5% reported; 20.2% organic ex–CSL Adjusted Operating Margin %1 36.2% 35.6% +60bps Blood Center Q3 2026 Q3 2025 Y/Y (19.6%) reported; Revenue $56.6M $70.3M 2.8% organic Adjusted Operating Ma
Slide 8: Balance Sheet and Cash Flow Metrics
Balance Sheet and Cash Flow Metrics Cash from operations (in millions) (in millions) 12/27/25 3/29/25 FCF CapEx and Other 4 $339 Cash & cash equivalents $363 $307 $79 Working capital $404 $357 $222 Total debt $1,225 $1,225 $57 Net debt1 $861 $918 $129 $260 $94 $25 Available credit2 $749 $749 $19 $16
Slide 9: Full Year Fiscal 2026 Guidance
Full Year Fiscal 2026 Guidance Previous February 2026 Revenue guidance by segment: • Plasma: (2 – 4%) reported; 17 – 19% organic growth, ex-CSL. Revenue (Reported) (1 – 4%) (1 – 3%) • Blood Center: (16 – 18%) reported; 1 – 3% organic growth. • Hospital: ~4% reported; ~4% organic growth. Organic grow
Slide 10: Appendices
Appendices © 2026 Haemonetics Corporation
Slide 11: Appendix A: Reconciliation of GAAP to Organic and Organic ex-CSL Revenue Growth Rates
Appendix A: Reconciliation of GAAP to Organic and Organic ex-CSL Revenue Growth Rates 2025 CSL US Organic Currency Acquisitions & Organic ($ millions) Q3 2026 Q3 2025 Reported growth Disposable growth, impact Divestitures1 growth Revenue2 ex-CSL Plasma $138.9 $134.2 3.5% 0.7% – 2.8% (17.4%) 20.2% Ap
Slide 12: Appendix B: Reconciliation of GAAP to Organic and Organic ex-CSL Fiscal Year 2026 Revenue
Appendix B: Reconciliation of GAAP to Organic and Organic ex-CSL Fiscal Year 2026 Revenue Guidance Plasma Blood Center Hospital Total Company Reported (2 – 4%) (16 – 18%) ~4% (1 – 3%) Currency impact – ~1% – ~1% Acquisitions & Divestitures1 – (19%) – (4%) Organic (2 – 4%) 1 – 3% ~4% 0 – 2% CSL 2025
Slide 13: Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Fiscal 2026 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Fiscal 2026 Financial Results Interest and Provision Earnings Operating Operating Net income Gross profit other (benefit) for per diluted ($ millions) expenses income (loss) (loss) expense income taxes share Reported $202.4 $135.0 $67.4 ($7.4) $15.2
Slide 14: Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Fiscal 2025 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Fiscal 2025 Financial Results Interest and Earnings Operating Operating Provision for ($ millions) Gross profit other Net income per diluted expenses income income taxes expense share Reported $193.5 $134.5 $59.0 ($9.1) $12.4 $37.5 $0.74 Amortization
Slide 15: Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Year-to-Date Fiscal 2026 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Year-to-Date Fiscal 2026 Financial Results Interest and Provision Earnings Operating Operating Net income ($ millions) Gross profit other income (benefit) for per diluted expenses income (loss) (loss) (expense) income taxes share Reported $589.4 $409
Slide 16: Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Year-to-Date Fiscal 2025 Financial Results
Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Year-to-Date Fiscal 2025 Financial Results Interest and Provision Earnings Operating Operating Net income ($ millions) Gross profit other income (benefit) for per diluted expenses income (loss) (loss) (expense) income taxes share Reported $555.9 $405
Slide 17: Appendix D: Reconciliation of Cash Flows
Appendix D: Reconciliation of Cash Flows ($ millions) Q3 2026 Q3 2025 FY 2026 YTD FY 2025 YTD Free Cash Flow Reconciliation Cash provided by operating activities $93.6 $43.8 $222.3 $65.2 Capital expenditures ($6.3) ($8.5) ($15.1) ($23.6) Additions to Haemonetics equipment ($13.4) ($5.9) ($42.6) ($12
Slide 18: Appendix E: Reconciliation of Non-GAAP of TTM Financial Results
Appendix E: Reconciliation of GAAP to Non-GAAP of TTM Financial Results1 TTM 2026 TTM 2025 ($ millions) Net income Net income (loss) (loss) Reported $175.4 $130.1 Amortization of acquired intangible assets $33.7 $35.5 Amortization of fair value inventory step up $6.4 $11.8 Acquisition, Integration,
Slide 19: Appendix F: Reconciliation of Segment Operating Income (1 of 2)
Appendix F: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2) Q3 2026 Q3 2025 Net revenues: Plasma $138.9 $134.2 Blood Center $56.6 $70.3 Hospital $143.5 $144.0 Total net revenues $339.0 $348.5 Significant segment expenses and operating performance: Plasma Cost of g
Slide 20: Appendix F: Reconciliation of Segment Operating Income (2 of 2)
Appendix F: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2) Q3 2026 Q3 2025 Corporate and unallocated expenses Amortization of acquired assets ($12.3) ($15.6) Integration and transaction costs ($1.7) ($0.2) Restructuring and restructuring related costs ($1.5) ($5.